✦ LIBER ✦

Anti-angiogenesis agents in metastatic or recurrent cervical cancer

✍ Scribed by Bradley J. Monk; Lyndsay J. Willmott; Daniele A. Sumner

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Chemotherapy for recurrent, metastatic,

✍ H.W. HIRTE; J.E. STRYCHOWSKY; T. OLIVER; M. FUNG-KEE-FUNG; L. ELIT; A.M. OZA 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 114 KB

Irinotecan and cisplatin as first line c

✍ Chitapanarux, I.; Lorvidhaya, V.; Tonusin, A.; Sukthomya, V.; Charuchinda, C.; P 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 192 KB

Chemotherapy in recurrent or advanced ce

✍ M. Gonzalez Viciedo; C. Navarro; B. Certa; R. Yazigi; R. Castilla; J. Garrido; S 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 169 KB

Weekly topotecan as second- or third-lin

✍ Jaime Coronel; Lucely Cetina; Myrna Candelaria; Aurora González-Fierro; Daimy Ar 📂 Article 📅 2008 🏛 Springer US 🌐 English ⚖ 194 KB

Anti-EGFR–targeting agents in recurrent

✍ Fausto Petrelli; Sandro Barni 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 519 KB

Paclitaxel plus oxaliplatin for recurren

✍ Dennis Yi-Shin Kuo; Stephanie V. Blank; Paul J. Christos; Mimi Kim; Thomas A. Ca 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 161 KB